Zhu et al. [3] revealed the expression, prognostic value, potential functional networks, protein interactions, and immune infiltration of MTFR2 (mitochondrial fission regulator 2) in GC, concluding that MTFR2 may be a potential prognostic marker and therapeutic target for GC patients. Here, MTFR2 is linked to gastric cancer.